Results 61 to 70 of about 1,866 (169)

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?

Dermatology Reports
According to the Italian Medicines Agency (AIFA) guidelines, patients with moderate-to-severe psoriasis can access biological therapies in case of treatment failure or contraindication to at least one conventional systemic treatment. However, no studies
Ilaria Salvi, Alexandra M. G. Brunasso, Franco Castelli, Andrea Michelerio, Paolo Pella, Marco Rubatto, Paolo Dapavo, Emanuele Cozzani, Martina Burlando   +8 more
doaj   +1 more source

Dissecting Cellulitis and Hidradenitis Suppurativa: Two Diseases or One Follicular‐Occlusion Spectrum?

International Journal of Dermatology, EarlyView.
Graphical abstract summarizing evidence that dissecting cellulitis of the scalp (DC) and hidradenitis suppurativa (HS) may represent site‐modified expressions of a shared follicular‐occlusion pathway, highlighting convergent clinical, histopathologic, and therapeutic features, the diagnostic‐context paradox, and the need for paired molecular studies ...
Giuseppe Gallo, Federica Repetto, Orsola Crespi, Isotta Giunipero di Corteranzo, Luca Mastorino, Pietro Quaglino, Simone Ribero   +6 more
wiley   +1 more source

Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis, Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre‐André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos‐Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John R. Ingram, Vaiva Jarienè, Gregor B. E. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. L. Saunte, Sylke Schneider‐Burrus, Mariano Suppa, Jacek Szepietowski, Andrea Szegedi, Simon Francis Thomsen, Thrasyvoulos Tzellos, Anastasia Trigoni, Hessel H. Van Der Zee, Kelsey Van Straalen, Skaidra Valiukevičiene, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis   +54 more
wiley   +1 more source

Bimekizumab Reinitiation Following Treatment Interruption Between Two Open‐Label Extension Periods: A North American Study in Participants With Moderate to Severe Plaque Psoriasis

Dermatologic Therapy
People with moderate to severe plaque psoriasis receiving long‐term biologic treatment may experience interruptions. It is important to assess response maintenance during interruptions and response recapture upon reinitiation.
Phoebe Rich, Seth Forman, Benjamin Ehst, Melinda Gooderham, José Manuel López Pinto, Markus Kaspar, Sarah Kavanagh, Kim A. Papp   +7 more
doaj   +1 more source

Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis

Patient Preference and Adherence, 2023
Alan Kivitz,1 Alicia M Ellis,2 Vishvesh Shende,3 Jérémy Lambert,4 Daljit Tatla2 1Altoona Center for Clinical Research, Duncansville, PA, USA; 2UCB Pharma, Raleigh, NC, USA; 3UCB Pharma, Slough, UK; 4UCB Pharma, Colombes, FranceCorrespondence: Daljit ...
Kivitz A, Ellis AM, Shende V, Lambert J, Tatla D   +4 more
doaj  

Therapeutic Inertia in Hidradenitis Suppurativa: Could Defensive Medicine Play a Role?

JEADV Clinical Practice, EarlyView.
Anju George, Alejandro Molina‐Leyva
wiley   +1 more source

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos, Vincent Piguet, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Victoria Shodimu, Abby Paine, Brian Kirby, Haley B. Naik   +9 more
wiley   +1 more source

Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies [PDF]

Objectives Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with psoriatic arthritis (PsA). Here, we report an additional year of
Manente, Myriam, Bajracharya, Rajan, Mease, Philip J, Gossec, Laure, Tanaka, Yoshiya, Asahina, Akihiko, Proft, Fabian, McInnes, Iain B, Ritchlin, Christopher T, Goldammer, Nadine, Coarse, Jason, Ink, Barbara, Landewé, Robert B M, Merola, Joseph F, Coates, Laura C   +14 more
core   +1 more source

Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study—IL PSO (Italian Landscape PSOriasis)

Dermatologic Therapy
Several studies have demonstrated that psoriasis severity is generally greater in male patients, but it is unclear whether this gender difference may affect short-term therapeutic response.
H. Gioacchini, A. Rossi, M. Esposito, E. Vagnozzi, M. Fargnoli, P. Gisondi, F. Bellinato, C. Assorgi, P. Brianti, S. Mercuri, M. Burlando, E. Cozzani, Giovanna Brunasso, S. Caccavale, A. Balato, G. Caldarola, C. De Simone, E. Campione, A. Giunta, F. Tonon, M. Venturini, C. Carrera, A. Marzano, A. Carugno, P. Sena, Antonio Costanzo, A. Narcisi, F. Cusano, P. Dapavo, P. Quaglino, A. Dattola, A. Richetta, F. Gaiani, P. Malagoli, M. Megna, L. Potestio, E. Mortato, F. Loconsole, F. Romano, A. Faragalli, R. Gesuita, T. Bianchelli, F. Diotallevi, D. Orsini, A. Campanati   +44 more
semanticscholar   +1 more source